Keywords: cor, shares, fall, analyst, says, reopro, remains
COR shares fall as analyst says ReoPro remains benchmark drug in its class
Article | 01 June 2000
COR Therapeutics saw its US shares slide more than 20% to $52.88 lastweek after an analyst's report on its glycoprotein IIb/IIIa ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
